Unither To Acquire UCB New York Plant
Unither Pharmaceuticals will acquire an UCB Rochester, NY pharmaceutical plant used to liquid pharmaceutical products.
Unither Pharmaceuticals, a sterile unit-dose manufacturer, will acquire an UCB pharmaceutical plant in Rochester, NY. The plant employs 250 people and mainly manufacturers liquid pharmaceutical products. This acquisition is a part of Unither's strategy to become a pharmaceutical global player and particularly in blow/fill/seal (BFS) technology. Under the agreement, Unither will continue manufacturing UCB products, and all Rochester's employees will be offered the opportunity to work for Unither. While manufacturing UCB products, Unither intends to install BFS and stick-pack technologies in the Rochester plant to provide its clients or US prospects with locally made products.The transaction is expected to be completed in the fourth quarter of this year, according to a Unither ref="http://www.unither-pharma.com/en/corporate-news/259-unither-will-acquire-ucb-pharmaceutical-plant-in-rochester">press release.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
